



[Science](#)[Education](#)[Patient Care](#)

[Our Society](#)[Our Mission, Vision & Values](#)[EBMT Membership 2025](#)[Organisational Structure 2025](#)[Financial Highlights 2025](#)[EBMT Partners](#)

Breadcrumb

1. [Home](#)

Entity Print



Donal McLornan
CMWP Chair
United Kingdom

Major achievements

Overall, 2025 was a highly productive year for the CMWP. We continued to refine our **study portfolio** to enhance scientific output and prioritise contemporary research. The CMWP published **10 papers**, including international panel recommendations on allo-HCT in MDS and “nonclassical” MPNs and MDS/MPNs. In addition, the CMWP presented **oral and poster abstracts** at several high-impact international

meetings, including EBMT25, ASH25, iwCLL25, as well as national haematological congresses. During the Practice Harmonisation & Guidelines Committee (PH&G) Meeting in Berlin, the CMWP continued work on **international recommendations**, including those addressing donor-derived haematologic neoplasms arising after allo-HCT, MDS/MPN, and T-cell prolymphocytic leukaemia in the allo-HCT setting.

The CMWP held highly productive **Business and Educational meetings** in Florence and more recently in Rome, alongside the ADWP in September 2025. The joint **CMWP & ADWP educational meeting**, approached from a “chronic malignancies perspective,” focused on current allo-HCT guidelines for MDS. Additional key topics included diagnostic and prognostic aspects of MDS, presented by invited guest Professor Mario Cazzola, who summarised major advances in MDS genomics. Professor Jaroslaw Maciejewski provided a translational perspective, shifting the focus from clinical practice to laboratory research, while Professor Maria Teresa Voso discussed therapeutic strategies for MDS outside the transplant setting. Participants also gained insights into optimising allo-HCT outcomes for MDS, including bridging strategies, conditioning regimens, immunosuppression, and post-transplant treatments. Further high-quality and contemporary presentations addressed VEXAS syndrome and autoimmune disorders in CMML, highlighting the overlap between CMWP and ADWP activities. In addition, the implementation of bispecific antibodies in the therapeutic armamentarium of multiple myeloma was clearly presented by Dr Patrick Hayden.

Future CMWP educational meetings are planned for Barcelona in November 2026, alongside the ALWP, and we look forward to welcoming you to what promises to be an exciting and innovative event.

Finally, I would like to acknowledge the entire **CMWP team**, including all principal investigators, subcommittees, and the data management, programming, and statistical teams, as well as all contributing members who have worked tirelessly on our studies. Their outstanding expertise, dedication, and collaborative spirit have enabled us to deliver robust evidence for the community. As I enter my final months as CMWP Chair, I wish the incoming Chair every success in leading this exceptional group forward.



Educational Meeting "Advancements in cellular therapy for Autoimmune Diseases and Chronic Haematological Malignancies"
18-20 September 2025, Rome, Italy



Practice Harmonisation & Guidelines Committee Meeting - October 2025,
Berlin, Germany



Practice Harmonisation & Guidelines Committee Meeting - October 2025, Berlin, Germany

Principal research studies

[Development of a prognostic model for survival after allogeneic hematopoietic cell transplantation \(allo-HCT\) in patients with myelodysplastic neoplasms \(MDS\) using machine learning](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Myelodysplastic \(MDS\) or MDS/MPN](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Donal P. McLornan, Carmelo Gurnari, Adrián Mosquera Orgueira, Marie Robin](#)

[Development of a prognostic model for estimation of survival after allogeneic hematopoietic cell transplantation \(allo-HCT\) in patients Chronic Myelomonocytic](#)

Leukaemia utilizing Machine Learning

Study type

Retrospective Studies

Diseases

Myelodysplastic (MDS) or MDS/MPN

Group

Chronic Malignancies Working Party (CMWP)

Type of treatment

Allogeneic

Principal investigator

Marie Robin, Adrián Mosquera Orgueira, Francesco Onida, Carmelo Gurnari, Donal P. McLornan

Del 17p Multiple myeloma (MM) patients who underwent autologous stem cell transplantation in EBMT centres between 2016 and 2022

Study type

Retrospective Studies

Diseases

Multiple Myeloma (MM) or other Plasma Cell Disorder (PCD)

Group

Chronic Malignancies Working Party (CMWP)

Type of treatment

Autologous

Principal investigator

Patrick Hayden

Analysis of Characteristics, Outcome and Risk Factors of Patients with Myelodysplastic Syndrome undergoing a Second Allogeneic Transplantation after Relapse from First AlloSCT

Study type

Retrospective Studies

Diseases

Myelodysplastic (MDS) or MDS/MPN

Group

Chronic Malignancies Working Party (CMWP)

Type of treatment

Allogeneic

Principal investigator

Giuliano Filippini Velazquez/Christoph Schmid

[Outcomes of Plasma Cell Myeloma Patients with t\(4;14\) who underwent Autologous Hematopoietic Cell Transplantation](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Multiple Myeloma \(MM\) or other Plasma Cell Disorder \(PCD\)](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[Type of treatment](#)

[Autologous](#)

[Principal investigator](#)

[Joanna Drozd-Sokolowska/Patrick Hayden](#)

Key publications

[2025](#)

[Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[Other society](#)

[1st listed author](#)

[Carmelo Gurnari](#)

[Journal](#)

[Blood.](#)

[2025](#)

[Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[Practice Harmonisation and Guidelines Committee](#)

[1st listed author](#)

[Nicola Polverelli](#)

[Journal](#)

[Blood.](#)

[2025](#)

[Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis](#)

Group

Chronic Malignancies Working Party (CMWP)

1st listed author

Juan Carlos Hernández-Boluda

Journal

Blood.

2025

Conditioning intensity in myelodysplastic patients aged \geq 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMT

Group

Chronic Malignancies Working Party (CMWP)

1st listed author

Noureddine Henoun Loukili

Journal

Bone Marrow Transplant.

2025

Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Group

Chronic Malignancies Working Party (CMWP)

1st listed author

Juan Carlos Hernández-Boluda

Journal

Am J Hematol.

See the full list of the CMWP 2025 publications



Indicators

	2023	2024	2025
Impact factor	151.07	170.20	111.50
Oral presentations	9	3	8
Poster presentations	9	8	6
Educational events	2	2	3

Major educational events



[Event](#)

51st Annual Meeting of the FBM



[Event](#)

Advancements in cellular therapy for Autoimmune Diseases and Chronic Haematological Malignancies

Sep 18, 2025 - Sep 20, 2025 / Rome, Italy

Discover more

VISIT THE CMWP WEBPAGE